Suggested remit To appraise the clinical and cost effectiveness of lumasiran within its marketing authorisation for treating primary hyperoxaluria type 1.
 
Status Proposed
Process STA 2018
ID number 3765

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
11 June 2021 Please note that following on from a request received from the company, the timelines for this evaluation have been revised and it is now anticipated to begin in early November 2021 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-January 2022. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
15 January 2021 Please note that following on from a request received from the company, the timelines for this evaluation have been revised and it is now anticipated to begin in mid-May 2021 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early July 2021. Publication of this topic is expected to be in mid-March 2022. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
24 July 2020 (14:00) Scoping workshop (Manchester)
05 June 2020 - 03 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance